Value of surgical pilot and feasibility study protocols

K. Fairhurst1, J. M. Blazeby1, S. Potter1, C. Gamble2, C. Rowlands1 and K. N. L. Avery1

1Centre for Surgical Research and Medical Research Council (MRC) ConDuCT-II Hub for Trials Methodology Research, Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, and 2MRC North West Hub for Trials Methodology Research, University of Liverpool, Liverpool, UK

Correspondence to: Miss K. Fairhurst, Centre for Surgical Research, Department of Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK (e-mail: katherine.fairhurst@bristol.ac.uk)

Background: RCTs in surgery are challenging owing to well established methodological issues. Well designed pilot and feasibility studies (PFS) may help overcome such issues to inform successful main trial design and conduct. This study aimed to analyse protocols of UK-funded studies to explore current use of PFS in surgery and identify areas for practice improvement.

Methods: PFS of surgical interventions funded by UK National Institute for Health Research programmes from 2005 to 2015 were identified, and original study protocols and associated publications sourced. Data extracted included study design characteristics, reasons for performing the work including perceived uncertainties around conducting a definitive main trial, and whether the studies had been published.

Results: Thirty-five surgical studies were identified, of which 29 were randomized, and over half (15 of 29) included additional methodological components (such as qualitative work examining recruitment, and participant surveys studying current interventions). Most studies focused on uncertainties around recruitment (32 of 35), with far fewer tackling uncertainties specific to surgery, such as intervention stability, implementation or delivery (10 of 35). Only half (19 of 35) had made their results available publicly, to date.

Conclusion: The full potential of pretrial work to inform and optimize definitive surgical studies is not being realized.

Presented to the International Clinical Trials Methodology Conference/Annual Meeting of the Society for Clinical Trials, Liverpool, UK, May 2017, and the Annual Meeting of the Society for Clinical Trials, Portland, Oregon, USA, May 2018; published in abstract form as Trials 2017; 18(Suppl 1): P16 and Clinical Trials 2018; 15(Suppl 2): 118 (A82)

Paper accepted 12 February 2019
Published online 10 May 2019 in Wiley Online Library (www.bjs.co.uk). DOI: 10.1002/bjs.11167

Introduction

High-quality RCTs are necessary to inform evidence-based surgical practice. Surgical trials are challenging to do owing to established methodological issues extending beyond those of RCTs in other areas1–4. Challenges specific to surgical RCTs include uncertainties around the stability and/or standardization of the intervention, selection and/or measurement of relevant clinical and patient-reported outcomes, and issues surrounding patient recruitment such as clinician and patient equipoise5–7. These specific challenges, combined with surgeons' lack of familiarity with RCTs and the perception that participation can be onerous, may mean that trials are not initiated, conducted efficiently or completed on time and on target.

Well designed pilot and feasibility studies (PFS) may help to overcome challenges associated with undertaking RCTs in surgery, by allowing uncertainties to be addressed, and optimal design of the main trial to be determined8–10. Previous methodological work has considered the use and misuse of PFS in general. Several checklists have been developed11–16 to identify and categorize specific reasons for undertaking pilot work, with the aim of guiding researchers into considering these for their study. More recently, guidelines for improved reporting of PFS, in the form of an extension to the CONSORT statement17, have been published. Integral to the development of these guidelines was the publication of a conceptual framework18 to promote understanding by defining the purpose and scope of different types of PFS in preparation for RCTs. These guidelines were, however, mostly theoretical,
with no specific recommendations for the use of PFS in surgery.

Some published recommendations have provided more practical guidance regarding the use of PFS in surgery. The Medical Research Council (MRC) framework\textsuperscript{19} for developing and evaluating all complex interventions (defined as interventions with multiple components acting both independently and interdependently) includes surgery. Within this framework, undertaking PFS before full-scale evaluation of surgical interventions in a definitive trial is considered vital preparatory work\textsuperscript{19}. The IDEAL (Idea, Development, Exploration, Assessment and Long-term follow-up) framework\textsuperscript{20–22} also provides recommendations specific to the evaluation of novel surgical interventions from first in man to long-term studies, and suggests study designs and issues to be considered at each stage of evaluation. Both the MRC and, more specifically for surgery, the IDEAL recommendations discuss PFS as part of a larger framework for the development and assessment of new complex interventions, and list several elements of the design of PFS.

Although PFS are thought to be beneficial and are endorsed as part of the strategic guidance discussed, there is uncertainty regarding exactly how they influence the design and conduct of successful RCTs\textsuperscript{22}. At a fundamental level, published literature suggests that the wider surgical community may not understand the concept of PFS, with evidence of small, underpowered RCTs often mislabelled as pilot or feasibility studies\textsuperscript{11,14,21}. Such studies often fail to address baseline feasibility issues such as considering whether a main trial is possible, and instead focus on formal hypothesis testing\textsuperscript{24–28}. Further work is therefore needed to understand when and how PFS may be used optimally to inform future main trials in surgery.

Development of guidance that addresses the challenges associated with undertaking surgical PFS requires understanding of the current use of such studies in surgery. As PFS are often poorly reported, a traditional systematic review of surgical PFS is unlikely to be informative beyond what is already known. Major research funders are increasingly recognizing the importance of well designed PFS in informing main trial design. It was therefore hypothesized that protocols of competitively funded PFS may provide more informative insights into the current use of PFS in surgery, and into how pretrial work may be used to inform future definitive studies. The aim of this paper was to analyse protocols of successfully funded surgical PFS. The purpose of this review was to identify how PFS are currently used, consider whether their use is appropriate, and envisage how the use of PFS could be further improved.

Methods

A systematic analysis of the protocols of PFS of surgical interventions funded by the UK National Institute for Health Research (NIHR) was undertaken.

Characteristics of information sources, search strategy and screening

The UK NIHR Health Technology Assessment (HTA) and Research for Patient Benefit (RfPB) programmes were selected to identify PFS of surgical interventions. These programmes are established major national funders of high-quality patient-centred research, having funded trials for 25 and 12 years respectively. Both programmes fund definitive evaluations of the clinical and cost-effectiveness of interventions, as well as feasibility studies to inform future definitive trials. They have publicly available and searchable databases of funded studies\textsuperscript{29,30}. Given the scope and longevity of both programmes, it was hypothesized that each would have funded surgical PFS, providing a sample of potentially well designed work from which to explore the role of PFS in surgery, and study their impact on main trial design and conduct.

The HTA and RfPB databases were searched for surgical PFS. Titles and abstracts were screened in duplicate, with any issues resolved by discussion and/or with senior input where necessary. Agreement was reached on inclusion or exclusion for 1283 studies (95.7 per cent) at the first attempt. Protocols for all included HTA studies were downloaded from the HTA website and those for all included RfPB studies (apart from 1 available online) were obtained by contacting the chief investigator of each study directly. Additional publications relating to included studies were identified by searching for links to published outputs on the NIHR website (HTA only), and using the study title, acronym and chief investigator name to search on PubMed, Google Scholar and the ISRCTN trials registry online.

Inclusion and exclusion criteria

Protocols of all surgical PFS funded by the NIHR HTA and RfPB programmes between 1 January 2005 and 31 December 2015 were included. In the absence of universally adopted definitions of surgical interventions and PFS, for the purposes of this review, pilot/feasibility work was defined as: any research that is undertaken before a main study and is explicitly intended to inform the design and/or conduct of a future main study, where main study is defined as a definitive study or RCT of an intervention(s). A surgical intervention was defined as a

© 2019 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd.
Fig. 1 Flow diagram showing selection of articles for review

Identified

Studies identified by searching HTA database
n = 703

Studies identified by searching RfPB database
n = 638

Screening

Studies excluded after screening n = 610
1: n = 543
2: n = 19
3: n = 17
3a: n = 31

Studies excluded after screening n = 655
1: n = 572
2: n = 46
3: n = 11
3a: n = 26

Eligibility

Studies assessed for eligibility n = 48

Studies excluded n = 2
No existing protocol n = 1
No surgical intervention in study n = 1

Studies excluded n = 1
No existing protocol n = 1

Studies excluded n = 37
Internal pilot studies n = 29
Systematic reviews (not meeting definition of pilot/feasibility work) n = 8

Eligible studies n = 28

Studies excluded n = 2
No existing protocol n = 1
No surgical intervention in study n = 1

Studies excluded n = 1
Internal pilot study n = 1

RfPB studies included n = 55

HTA studies included n = 10

Total no. of studies included n = 35
Randomized n = 29
Non-randomized n = 6

Reasons for exclusion: 1, not a surgical intervention; 2, surgical intervention, not pilot/feasibility work; 3, surgical intervention is a co-intervention; 3a, surgical intervention is a co-intervention and not pilot/feasibility work. NIHR, National Institute for Health Research; HTA, Health Technology Assessment; RfPB, Research for Patient Benefit.

diagnostic, therapeutic or adjunctive invasive intervention performed by a trained clinician, using hands, instruments and/or devices, and included operative, radiological and endoscopic procedures.

Internal pilot studies were excluded owing to growing opinion among trial methodologists that internal pilots do not meet the true definition of pilot studies. This is because internal pilots are very distinct from external pilots in their methodology, being designed and funded as a part of a main trial with all data generated from this first phase contributing to the final analysis. Internal pilots are, therefore, most often used when no substantive changes to key components of the trial, such as the intervention or outcomes, are anticipated. In addition, study protocols of RCTs with an internal pilot phase usually include only limited detail regarding the internal pilot phase itself, such as a list of proposed progression criteria. It was therefore
considered that a review of trial protocols with an integrated internal pilot phase would be of limited value for the purpose of this work. Also excluded were funded systematic reviews that did not state any intention to inform a future definitive study, and studies that focused on the evaluation of co-interventions to surgery, for example the administration of anaesthetic drugs, and postoperative rehabilitation or enhanced recovery programmes. This was because the primary focus of this work was to explore the specific difficulties surrounding studies of surgical interventions.

Data extraction and analyses

Data were extracted using a standard database developed in Microsoft Excel® (Microsoft, Redmond, Washington, USA), including general study characteristics, available data sources in addition to the study protocol (published papers) and the surgical specialty of the study. The data extraction form is available in Appendix S1 (supporting information). Details of the study design (randomized or non-randomized; quantitative or qualitative) and conduct, including characteristics of the patient population, were extracted. A framework was developed for capturing the uncertainties and challenges regarding the viability of a future main trial, informed by expert knowledge and previous methodological work regarding the design, definitions and reporting of PFS11–18,32–34, published MRC guidelines19 and the IDEAL framework20,21. All possible reasons identified for undertaking PFS were grouped into five key domains: main trial design; logistics; recruitment; intervention; and outcomes. The domains were constructed and ordered according to how extraction progressed, with cross-checking between authors. Special consideration was given to uncertainties and challenges considered more specific and/or relevant to surgical trials. Results were analysed in Microsoft Excel®. Descriptive statistics are reported with comparison between the HTA and RfPB, and randomized and non-randomized cohorts where relevant.

Results

Screening

A total of 1341 funded studies were identified (703 HTA studies, 52.4 per cent), and 35 eligible studies (25 RfPB, 10 HTA) were included in the final analysis (Fig. 1). Additional data sources were available for 25 of the 35 studies; these included a published protocol paper for 13 of 35 studies and a paper reporting the PFS findings for 19 (Fig. 2). Publication rates of the study protocols were similar between funders (HTA 4 of 10, RfPB 9 of 25), although the results of HTA studies were published more often than those of RfPB studies (HTA 10 of 10, RfPB 9 of 25).

Study characteristics

Some 29 of 35 studies were randomized and six were non-randomized (Fig. 1), including qualitative work, national audit and cohort studies (Table 1). Randomized studies were more often multicentre and conducted by larger trial teams than non-randomized studies. Over half of the randomized studies (15 of 29) also included other types of pretrial work.

Reasons for conducting pilot/feasibility studies

Reasons for performing PFS are summarized in Table 2. Addressing uncertainties around trial recruitment was cited as the most common reason (32 of 35 studies; RfPB 23 of 25, HTA 9 of 10), followed by the overarching aim to determine whether a main trial was possible or necessary (27 of 35 studies; RfPB 17 of 25, HTA 10 of 10). Logistical issues (such as trial paperwork, resources needed, running multicentre studies) were considered in two-thirds of studies (23 of 35 studies; RfPB 16 of 25, HTA 7 of 10) and outcomes (for example selecting the primary outcome, determining important outcomes for patients) in less than half (15 of 35 studies; RfPB 11 of 25, HTA 4 of 10). Around half of the studies considered issues regarding the sample size for the main trial (for example assessing variability in...
Table 1 Design characteristics of the 35 pilot/feasibility studies in the review

| Surgical specialty of study       | Randomized studies (n = 29) | Non-randomized studies (n = 6) |
|-----------------------------------|-----------------------------|--------------------------------|
|                                   | RfPB (n = 22) | HTA (n = 7) | Total (n = 29) | HTA (n = 3) | RfPB (n = 3) | Total (n = 6) |
| Gastrointestinal                  | 8              | 1            | 9              | 2            | 0            | 2              |
| Urology                           | 3              | 2            | 5              | 0            | 0            | 0              |
| Cardiac                           | 3              | 0            | 3              | 0            | 0            | 0              |
| Orthopaedic                       | 2              | 2            | 4              | 0            | 0            | 0              |
| Obstetrics/gynaecology            | 2              | 0            | 2              | 0            | 1            | 1              |
| Maxillofacial/ENT                 | 2              | 1            | 3              | 0            | 1            | 1              |
| Plastics                          | 1              | 0            | 1              | 0            | 0            | 0              |
| Paediatrics                       | 1              | 1            | 2              | 0            | 1            | 1              |
| Breast                            | 0              | 0            | 0              | 1            | 0            | 1              |
| **No. of centres**                | 3 (1–23)       | 4 (2–10)     | 3 (1–23)       | 1 (1)        | 2 (1–65)     | 1 (1–65)       |
| 1                                 | 7              | 0            | 7              | 3            | 1            | 4              |
| 2–20                              | 14             | 7            | 21             | 0            | 1            | 1              |
| > 20                              | 1              | 0            | 1              | 0            | 1            | 1              |
| **Proposed no. of participants in study** | 50 (30–200) | 70 (60–144) | 60 (30–200) | n.a. | n.a. | n.a. |
| **Patient characteristics**       |                |               |                |               |               |                |
| Age                               |                |               |                |               |               |                |
| Adults                            | 19             | 5            | 24             | 2            | 2            | 4              |
| Children                         | 2              | 1            | 3              | 1            | 0            | 1              |
| Both                              | 1              | 1            | 2              | 0            | 1            | 1              |
| Sex                               |                |               |                |               |               |                |
| Male                              | 1              | 1            | 2              | 0            | 0            | 0              |
| Female                            | 3              | 0            | 3              | 1            | 1            | 2              |
| Both                              | 18             | 6            | 24             | 2            | 2            | 4              |
| Country                           |                |               |                |               |               |                |
| UK                                | 20             | 7            | 27             | 2            | 3            | 5              |
| Europe                            | 2              | 0            | 2              | 0            | 0            | 0              |
| Worldwide                         | 0              | 0            | 0              | 1            | 0            | 1              |
| **No. of personnel in trial team** | 6.5 (4–19)     | 9.5 (0–24)   | 9 (0–24)       | 1 (0–12)     | 7 (2–25)     | 5.5 (0–25)     |
| Non-randomized pretrial work      |                |               |                |               |               |                |
| Qualitative interviews            | 9              | 61           | 70             | 15           | 3            | 3              |
| Participant/researcher survey     | 8              | 6            | 14             | 2            | 2            | 4              |
| Economic modelling                | 1              | 1            | 2              | 2            | 3            | 5              |
| Systematic review                 | 0              | 0            | 0              | 1            | 0            | 1              |
| National audit                    | 0              | 0            | 0              | 0            | 1            | 1              |
| Cohort study                      | 0              | 0            | 0              | 0            | 1            | 1              |

*Values are median (range). †Some studies planned more than one type of non-randomized work; ‡most studies planned more than one type of non-randomized work. RfPB, Research for Patient Benefit; HTA, Health Technology Assessment; ENT, ear, nose and throat; n.a., not applicable.

outcomes) (19 of 35 studies; RfPB 17 of 25, HTA 2 of 10) and costs/funding for the main trial (16 of 35 studies; RfPB 14 of 25, HTA 2 of 10).

Eleven of the 35 studies (all RfPB-funded) aimed to collect data regarding the safety or effectiveness of an intervention to inform the main trial and, of these, almost three-quarters (8 of 11) specified plans for formal hypothesis testing by comparing the intervention(s) and/or control groups to test effectiveness and/or safety, which is not recommended for PFS.

One-quarter (10 of 35 studies; RfPB 6 of 25, HTA 4 of 10) sought to explore uncertainties around the surgical intervention itself, such as intervention development, stability, delivery and the surgical learning curve. Of these ten studies, six were considering surgery versus no surgery, and four were considering a novel surgical technique versus an established method (Table 3). Of the ten studies specifically planning to evaluate a new surgical technique, only four aimed to address uncertainties surrounding the intervention. These uncertainties included: documenting the
### Table 2: Rationale as detailed in the protocol for the pilot and feasibility studies of surgical interventions included in the systematic analysis

| Area examined | Rationale                                                                 | No. of studies stating each rationale in the study protocol | No. of studies stating examination of each area in the study protocol |
|---------------|---------------------------------------------------------------------------|-------------------------------------------------------------|---------------------------------------------------------------------|
|               |                                                                           | RIPB (n = 25) (3 NR) | HTA (n = 10) (3 NR) | Total (n = 35) (6 NR) | RIPB (n = 25) | HTA (n = 10) | Total (n = 35) |
| **Main trial design** |                                                                           |                                         |                                         |                                         |                                         |                                         |                                         |
| To examine and test whether a main trial is possible | 14 (2) | 8 (1) | 22 (3) |                                      |                                          |                                          |                                          |
| To assess whether main trial is needed and/or produce a protocol | 3 (0) | 0 (2) | 3 (2) |                                      | 17 | 10 | 27 |
| To test whether the protocol can be adhered to and modify it as necessary | 2 (0) | 2 (0) | 4 (0) |                                      |                                          |                                          |                                          |
| To determine a sample size for the main trial | 3 (0) | 0 (0) | 3 (0) |                                      |                                          |                                          |                                          |
| **Sample size** |                                                                           |                                         |                                         |                                         |                                         |                                         |                                          |
| To estimate the variability in outcomes to help determine a sample size for the main trial | 15 (1) | 2 (0) | 17 (1) |                                      | 17 | 2 | 19 |
| **Costs/funding** |                                                                           |                                         |                                         |                                         |                                         |                                         |                                          |
| To assess/gather information on costs of performing the trial (direct and indirect) | 2 (0) | 0 (0) | 2 (0) |                                      |                                          |                                          |                                          |
| To perform/prepare for a cost-effectiveness analysis of the intervention(s) | 13 (1) | 2 (0) | 15 (1) |                                      | 14 | 2 | 16 |
| To provide information/evidence to funders | 1 (0) | 0 (0) | 1 (0) |                                      |                                          |                                          |                                          |
| **Safety and effectiveness data** |                                                                           |                                         |                                         |                                         |                                         |                                         |                                          |
| Preliminary data on safety to inform a main trial | 2 (0) | 0 (0) | 2 (0) |                                      |                                          |                                          |                                          |
| Information on adverse events | 4 (0) | 0 (0) | 4 (0) |                                      |                                          |                                          |                                          |
| Planned formal hypothesis testing of safety outcomes* | 3 (1) | 0 (0) | 3 (1) |                                      | 11 | 0 | 11 |
| Preliminary data on effectiveness to inform a main trial | 0 (0) | 0 (0) | 0 (0) |                                      |                                          |                                          |                                          |
| Planned formal hypothesis testing of effectiveness outcomes* | 7 (1) | 0 (0) | 7 (1) |                                      |                                          |                                          |                                          |
| **Logistics** |                                                                           |                                         |                                         |                                         |                                         |                                         |                                          |
| To test the logistics of multicentre studies | 5 (0) | 1 (0) | 6 (0) |                                      |                                          |                                          |                                          |
| To develop a research network as a resource for a future main trial | 1 (1) | 0 (0) | 1 (1) |                                      |                                          |                                          |                                          |
| To develop/test patient information content/forms/methods of delivery | 1 (0) | 3 (0) | 4 (0) |                                      |                                          |                                          |                                          |
| To develop/test data collection forms/methods | 13 (1) | 6 (1) | 19 (2) |                                      | 16 | 7 | 23 |
| To develop/test questionnaires/surveys | 5 (0) | 1 (0) | 6 (0) |                                      |                                          |                                          |                                          |
| To test response rates to questionnaires/surveys | 0 (0) | 0 (0) | 0 (0) |                                      | 16 | 7 | 23 |
| To prepare/plan/assess monitoring procedures | 0 (0) | 1 (0) | 1 (0) |                                      |                                          |                                          |                                          |
| To determine what resources are needed for a main trial (e.g. funding/staff) | 3 (0) | 0 (0) | 3 (0) |                                      |                                          |                                          |                                          |
| To assess the logistics of delivering an intervention as part of a trial in the NHS | 1 (0) | 0 (0) | 1 (0) |                                      |                                          |                                          |                                          |
| To test (novel) methods of blinding | 1 (0) | 1 (0) | 2 (0) |                                      |                                          |                                          |                                          |
| To assess proposed data analysis techniques | 1 (0) | 1 (0) | 2 (0) |                                      |                                          |                                          |                                          |
| To learn about the day-to-day running of a trial | 1 (0) | 0 (0) | 1 (0) |                                      |                                          |                                          |                                          |
Table 2 Continued

| Area examined | Rationale                                                                 | RI PB (n = 25) (3 NR) | HTA (n = 10) (3 NR) | Total (n = 35) (6 NR) | RI PB (n = 25) (3 NR) | HTA (n = 10) (3 NR) | Total (n = 35) |
|---------------|---------------------------------------------------------------------------|-----------------------|---------------------|-----------------------|-----------------------|---------------------|----------------|
| Recruitment   | To test/modify inclusion/exclusion/eligibility criteria                    | 2 (0)                | 0 (1)               | 2 (1)                 |                       |                     |                |
|               | To estimate the expected prevalence or rate of incident cases in the       | 1 (1)                | 1 (0)               | 2 (1)                 |                       |                     |                |
|               | population                                                                 |                       |                     |                       |                       |                     |                |
|               | To estimate the number to be screened and proportions of eligible patients| 9 (0)                | 3 (0)               | 12 (0)                |                       |                     |                |
|               | To assess numbers/rates of recruitment and consent                        | 17 (0)               | 5 (0)               | 22 (0)                | 23                    | 9                   | 32             |
|               | To test the randomization procedure                                       | 5 (0)                | 3 (0)               | 8 (0)                 |                       |                     |                |
|               | To test the acceptability of randomization/trial design                   | 12 (1)               | 5 (2)               | 17 (3)                |                       |                     |                |
|               | To determine the acceptability of the intervention to clinicians and patients | 12 (1)              | 4 (2)               | 16 (3)                |                       |                     |                |
|               | To assess rates of retention in the study                                 | 11 (0)               | 2 (0)               | 13 (0)                |                       |                     |                |
|               | To assess and monitor the development of an intervention and/or its stability | 2 (1)                | 1 (0)               | 3 (1)                 |                       |                     |                |
|               | To develop and test the implementation and delivery of the intervention   | 1 (0)                | 3 (0)               | 4 (0)                 |                       |                     |                |
|               | To train staff in delivery and assessment procedures                      | 1 (0)                | 0 (0)               | 1 (0)                 |                       |                     |                |
|               | To monitor the surgical learning curve                                    | 2 (1)                | 0 (0)               | 2 (1)                 | 6                     | 4                   | 10             |
|               | To test rates of crossover                                                | 0 (0)                | 1 (0)               | 1 (0)                 |                       |                     |                |
|               | To examine reasons for non-adherence/crossover for the main trial        | 2 (0)                | 0 (0)               | 2 (0)                 |                       |                     |                |
|               | To develop pathways and protocols for co-interventions                    | 0 (0)                | 0 (0)               | 0 (0)                 |                       |                     |                |
| Outcome       | To select the most appropriate primary outcome measure                    | 9 (1)                | 0 (0)               | 9 (1)                 |                       |                     |                |
|               | To develop and test a new outcome measure                                 | 0 (0)                | 0 (0)               | 0 (0)                 | 11                    | 4                   | 15             |
|               | To determine appropriate/importance/suitability of outcome measures for patients/clinicians | 3 (0)                | 4 (2)               | 7 (2)                 |                       |                     |                |

Values in parentheses are number of non-randomized (NR) studies. *Formal hypothesis testing to demonstrate the safety and/or effectiveness of an intervention is generally not recommended for pilot and feasibility studies because of the underpowered sample size (see discussion). RI PB, Research for Patient Benefit; HTA, Health Technology Assessment; NHS, National Health Service.

Table 3 Type of trial for studies that examined details of the surgical intervention and those that did not

| Type of trial | Studies examining the intervention (n = 10) | Studies not examining the intervention (n = 25) | Total (n = 35) |
|---------------|-------------------------------------------|-----------------------------------------------|----------------|
| Surgery versus no surgery | 6                                         | 9                                            | 15             |
| New/novel surgical technique versus surgery | 4                                         | 6                                            | 10             |
| Non-randomized pilot/feasibility work | 0                                         | 5                                            | 5              |
| Surgery versus surgery (both established techniques) | 0                                         | 4                                            | 4              |
| Surgery versus placebo and no surgery (2 arms) | 0                                         | 1                                            | 1              |
Discussion

This study demonstrated that the full potential of PFS to address the uncertainties and challenges specific to undertaking surgical trials is yet to be realized. The reasons most often cited by authors for performing PFS reflect the targeting of uncertainties generic to trials in general, such as recruitment, and considering whether a main trial is possible. Less than one-third of surgical PFS explored challenges of specific relevance to designing and conducting trials in surgery, such as uncertainties around the stability or delivery of the surgical intervention itself. Notably, of the ten studies aiming to evaluate a novel surgical intervention, only four addressed uncertainties surrounding the procedure, such as development of the new intervention, implementation and delivery of the intervention, and the effect of the surgical learning curve. Of equal importance is the finding that the role of PFS in surgery is still often misunderstood, with nearly one-quarter of studies planning to conduct formal hypothesis testing. Results of PFS in surgery are frequently under-reported, with almost half not publishing the results to date, despite the majority having completed before 2018. These findings indicate that there is a need for guidance regarding the scope and optimal use of PFS to promote main trial success and prevent research waste.

There are several possible reasons for the findings observed in this study. Conceivably, there may be confusion among surgeons around the value of PFS. In addition, it is possible that the design of PFS in funding applications is skewed towards reasons perceived as important to funders, such as demonstrating adequate recruitment and the feasibility of completing a main trial to time and target. It is likely that most trialists would acknowledge that recruitment is paramount to study success. However, there may be a lack of awareness amongst applicants of the many other potential uncertainties that can compromise the success of a main trial, particularly those around the intervention.

Previous guidance regarding the optimal design and conduct of PFS has been theoretical or generic. The IDEAL framework, for example, describes a pathway for new surgical interventions from first in man (stage 1) to long-term study (stage 4), with stage 2a (development) and 2b (exploration) studies considered to be PFS, focusing on addressing uncertainties before stage 3 assessment in a definitive RCT. The initial IDEAL publication, however, was largely theoretical with little practical guidance about how PFS should be performed. Recently published updated IDEAL recommendations now provide some clarification regarding the role of PFS in surgery as a result of recognition that the original IDEAL guidance published in 2009 had little impact on the design and conduct of surgical PFS. The updated IDEAL framework suggests several feasibility issues to consider in stage 2a/2b studies, including estimating effect size, defining intervention quality and standards, evaluating learning curves, exploring group differences, eliciting key stakeholder values and preferences, and analysis of adverse events. This list is far from exhaustive. The present analysis of protocols for NIHR-funded surgical PFS indicates that there are important additional issues regarding the design and conduct of surgical trials that may usefully be explored in PFS.

The findings of PFS are often not widely disseminated. This may reflect journal editors’ lack of appreciation of the value of pilot work and concerns about the quality or methodological rigour of pilot work in general. Introduction of open-access journals focused specifically on PFS such as Pilot and Feasibility Studies may address this. Researchers themselves may also fail to prioritize the reporting and dissemination of findings from PFS, which may be fuelled further by the decision to pursue (or not) the main trial. Notably, however, all ten HTA-funded studies identified in this review published their results. This is because studies funded by HTA are required to publish a report in the peer-reviewed Health Technology Assessment journal.

The scope of PFS in general has historically been narrow, focusing typically on issues relating to safety and efficacy or recruitment. A 2011 literature review of 50 pilot RCTs demonstrated that only 56 per cent of the studies addressed methodological issues in any depth. Another literature review of studies published between 2007 and 2008 found that up to 74 per cent of PFS performed and reported hypothesis testing for one or more variables (compared with 23 per cent (8 of 35) in the present study). There is now general acceptance that any suggestion of promise or significance should be reported with caution, given the underpowered sample size of most PFS, and the present examination of protocols perhaps demonstrates a growing, if not complete, understanding of this issue.
This study demonstrated some key limitations of PFS in surgery, but focused solely on studies funded by the NIHR HTA and RfPB funding streams. Other NIHR funding streams were considered but excluded as they do not commonly fund surgical research. Of the 29 studies funded via the 2012 NIHR-commissioned call for surgical research, for example, only four met the inclusion criteria of the present study. These four studies were funded by the RfPB programme and were therefore all included in this work. Although the NIHR HTA and RfPB programmes are the major funders of studies of surgical interventions in the UK, it is accepted that there are charities, for example the British Heart Foundation and Arthritis UK, which may fund such work. However, this would have been logistically challenging given that very few funders make study protocols publicly available. Conversely, the NIHR-funded protocols are likely to be of relatively high quality so may provide an overly positive perception of the quality of PFS in surgery.

Working collaboratively to design and perform pretrial work can deliver surgical PFS in a cost-effective and timely manner, and can advance the development of definitive studies. High-quality PFS may also be resource- and cost-effective, preventing waste by averting futile main trials, or providing information to improve the design and conduct of the main trial. The findings from this study indicate, however, that PFS in surgery are not currently used to their full potential.

Work is under way to incorporate the present study findings into a wider methodological project to develop guidelines to support surgical researchers in undertaking PFS. These are likely to build on existing guidance from the MRC, the IDEAL group and broader methodological work, but focus specifically on surgical PFS. It will be important to explore if and how PFS influence main trial design and conduct. This will be achieved by following these NIHR-funded PFS as they progress to main trials. The guidelines aim to provide researchers with clear and accessible information regarding how and when to undertake PFS, detail the key features to consider when designing and conducting PFS to inform a future main trial, and emphasize the importance of working collaboratively with trial methodologists to ensure that PFS address all uncertainties around future trial conduct accurately and wholly.

Acknowledgements

As this is not a traditional systematic review, the study was not preregistered with an analysis plan in an independent, institutional registry.

The authors acknowledge the chief investigators of all the included RfPB studies who kindly supplied study protocols in order that this work could be completed: P. Bhandari, J. Blazeby, M. Birchall, J. de Caestecker, A. Care, M. Crundwell, T. Davis, A. Dhar, S. Eldabe, K. Franks, A. Goyal, D. Griffin, E. Hall, P. Hull, K. Ismail, C. Knowles, A. Marchbank, H. Mostafid, S. Pereira, T. Pinkney, S. Potter, R. Prasad, P. Roderick, A. Sutcliffe (protocol available online), M. Tickle and S. Verma. They also thank M. Ashton-Key and A. Blatch-Jones at the NIHR Evaluation Trials and Study Co-ordination Centre for assistance with the Microsoft Excel database used for screening the HTA study cohort, and commenting on the protocol for this work.

This work was supported by a MRC Hub for Trials Methodology Research PhD studentship for K.F, J.M.B. and K.A. are supported by the NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol, and the MRC ConDuCT-II (Collaboration and innovation in Difficult and Complex randomized controlled Trials In Invasive procedures) Hub for Trials Methodology Research (MR/K0256/43/1). C.G. is supported by the MRC North West Hub for Trials Methodology Research at the University of Liverpool (MR/L004933/1). The views expressed are those of the authors and not necessarily those of the UK National Health Service, NIHR, Department of Health or MRC. S.P. is an NIHR Clinician Scientist and J.M.B. is an NIHR Senior Investigator.

Disclosure: The authors declare no conflict of interest.

References

1 Ergina PL, Cook JA, Blazeby JM, Boutron I, Clavien PA, Reeves BC et al. Challenges in evaluating surgical innovation. Lancet 2009; 374: 1097–1104.
2 Blencowe NS, Cook JA, Pinkney T, Rogers C, Reeves BC, Blazeby JM. Delivering successful randomized controlled trials in surgery: methods to optimize collaboration and study design. Clin Trials 2017; 14: 211–218.
3 Cook JA. The challenges faced in the design, conduct and analysis of surgical randomised controlled trials. Trials 2009; 10: 9.
4 McCulloch P, Taylor I, Sasaki M, Lovett B, Griffin D. Randomised trials in surgery: problems and possible solutions. BMJ 2002; 324: 1448–1451.
5 Donovan JL, de Salis I, Toerien M, Paramasivan S, Hamdy FC, Blazeby JM. The intellectual challenges and emotional consequences of equipoise contributed to the fragility of recruitment in six randomized controlled trials. J Clin Epidemiol 2014; 67: 912–920.
6 Donovan JL, Paramasivan S, de Salis I, Toerien M. Clear obstacles and hidden challenges: understanding recruiter
perspectives in six pragmatic randomised controlled trials. 
*Trials* 2014; **15**: 5.

7 Rooshenas L, Elliott D, Wade J, Jepson M, Paramasivan S, Strong S *et al*. ACST-2 study group; By-Band-Sleeve study group; Chemorad study group; CSAW study group; Optima prelim study group; POUT study group. Conveying equipoise during recruitment for clinical trials: qualitative synthesis of clinicians’ practices across six randomised controlled trials. *PLoS Med* 2016; **13**: e1002147.

8 Arnold DM, Webert KE, Adhikari NK, Cook DJ. Pilot trials in transfusion medicine. *Transfusion* 2009; **49**: 1293–1295.

9 Eldridge S, Bond C, Campbell M, Hopewell S, Thabane L, Lancaster G *et al*. Defining feasibility and pilot studies in preparation for randomised controlled trials: using consensus methods and validation to develop a conceptual framework. *Trials* 2015; **16**(Suppl 2): 087.

10 Thabane L, Hopewell S, Lancaster GA, Bond CM, Coleman CL, Campbell MJ *et al*. Methods and processes for development of a CONSORT extension for reporting pilot randomized controlled trials. *Pilot Feasibility Stud* 2016; **2**: 25.

11 Arain M, Campbell MJ, Cooper CL, Lancaster GA. What is a pilot or feasibility study? A review of current practice and editorial policy. *BMC Med Res Methodol* 2010; **10**: 67.

12 Kistin C, Silverstein M. Pilot studies: a critical but potentially misused component of interventional research. *JAMA* 2015; **314**: 1561–1562.

13 Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. *J Eval Clin Pract* 2004; **10**: 307–312.

14 Shanyinde M, Pickering RM, Weatherall M. Questions asked and answered in pilot and feasibility randomized controlled trials. *BMCMed Res Methodol* 2011; **11**: 117.

15 Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP *et al*. A tutorial on pilot studies: the what, why and how. *BMCMed Res Methodol* 2010; **10**: 1.

16 Tickle-Degnen L. Nuts and bolts of conducting feasibility studies. *Am J Occup Ther* 2013; **67**: 171–176.

17 Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L *et al*.; PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. *BMJ* 2016; **355**: i5239.

18 Eldridge SM, Lancaster GA, Campbell MJ, Thabane L, Hopewell S, Coleman CL *et al*. Defining feasibility and pilot studies in preparation for randomised controlled trials: development of a conceptual framework. *PLoS One* 2016; **11**: e0150205.

19 Medical Research Council. *Developing and Evaluating Complex Interventions: New Guidance*. London: Medical Research Council; 2008.

20 The IDEAL Collaboration. http://www.ideal-collaboration.net/ [accessed 28 November 2017].

21 McCulloch P, Altman DG, Campbell WB, Flum DR, Glasziou P, Marshall JC *et al*. No surgical innovation without evaluation: the IDEAL recommendations. *Lancet* 2009; **374**: 1105–1112.

22 Hirata A, Philippou Y, Blazeby J, Campbell B, Campbell M, Feinberg J *et al*. No surgical innovation without evaluation: evolution and further development of the IDEAL framework and recommendations. *Ann Surg* 2019; **269**: 211–220.

23 Loscalzo J. Pilot trials in clinical research: of what value are they? *Circulation* 2009; **119**: 1694–1696.

24 Frees SK, Aning J, Black P, Strauss W, Bell R, Chavez-Munoz C *et al*. A prospective randomized pilot study evaluating an ERAS protocol versus a standard protocol for patients treated with radical cystectomy and urinary diversion for bladder cancer. *World J Urol* 2018; **36**: 215–220.

25 Natung T, Keditso A, Shullai W, Goswami PK. Sutureless, glue-less conjunctival autograft versus conjunctival autograft with sutures for primary, advanced pterygia: an interventional pilot study. *J Clin Diag Res* 2017; **11**: NC04–NC07.

26 Perera AP, Howell AM, Sodergren MH, Farne H, Darzi A, Purkayastha S *et al*. A pilot randomised controlled trial evaluating postoperative packing of the perianal abscess. *Langenbecks Arch Surg* 2015; **400**: 267–271.

27 Till SR, Hobbs KA, Moulder JK, Steege JF, Siedhoff MT. McCall culdoplasty during total laparoscopic hysterectomy: a pilot randomized controlled trial. *J Minim Invasive Gynecol* 2018; **25**: 670–678.

28 Wijayasinghe N, Andersen KG, Kehlet H. Analgesic and sensory effects of the pecs local anesthetic block in patients with persistent pain after breast cancer surgery: a pilot study. *Pain Pract* 2017; **17**: 185–191.

29 National Institute for Health Research. *Research for Patient Benefit*. http://www.nihr.ac.uk/research-and-impact/research/nihr-studies/research-for-patient-benefit.htm [accessed 28 November 2017].

30 National Institute for Health Research. *Health Technology Assessment*. https://www.nihr.ac.uk/funding-and-support/funding-for-research-studies/funding-programmes/health-technology-assessment/ [accessed 28 November 2017].

31 Cook JA, Beard DJ, Cook JR, MacLennan GS. The curious case of an internal pilot in a multicentre randomised trial – time for a rethink? *Pilot Feasibility Stud* 2016; **2**: 73.

32 Lancaster GA, Campbell MJ, Eldridge S, Farrin A, Marchant M, Muller S *et al*. Trials in primary care: statistical issues in the design, conduct and evaluation of complex interventions. *Stat Methods Med Res* 2010; **19**: 349–377.

33 Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot studies in clinical research. *J Psychiatr Res* 2011; **45**: 626–629.

34 Van Teijlingen ER, Rennie AM, Hundley V, Graham W. The importance of conducting and reporting pilot studies: the example of the Scottish Births Survey. *J Adv Nurs* 2001; **34**: 289–295.

35 Eldridge S, Bond C, Campbell M, Lancaster G, Thabane L, Hopewell S. Definition and reporting of pilot and feasibility studies. *Trials* 2013; **14**(Suppl 1): O18.
36 Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L et al.; on behalf of the PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot Feasibility Stud 2016; 2: 64.

37 McCulloch P, Feinberg J, Philippou Y, Kolas A, Kehoe S, Lancaster G et al. Progress in clinical research in surgery and IDEAL. Lancet 2018; 392: 88–94.

38 Avery KN, Williamson PR, Gamble C, O’Connell Francischetto E, Davidson P et al.; members of the Internal Pilot Trials Workshop supported by the Hubs for Trials Methodology Research. Informing efficient randomised controlled trials: exploration of challenges in developing progression criteria for internal pilot studies. BMJ Open 2017; 7: e013537.

39 Lancaster GA. Pilot and feasibility studies come of age! Pilot Feasibility Stud 2015; 1: 1.

40 Leuck AM, Johnson JR, Hunt MA, Dhody K, Kazempour K, Ferrieri P et al. Safety and efficacy of a novel silver-impregnated urinary catheter system for preventing catheter-associated bacteriuria: a pilot randomized clinical trial. Am J Infect Control 2015; 43: 260–265.

41 Romero-Cerecero O, Zamilpa A, Tortoriello J. Pilot study that evaluated the clinical effectiveness and safety of a phytopharmaceutical elaborated with an extract of Ageratina pichinchensis in patients with minor recurrent aphthous stomatitis. J Ethnopharmacol 2015; 173: 225–230.

42 Woodhall SC, Nichols T, Alexander S, da Silva FC, Mercer CH, Ison C et al. Can we use postal surveys with anonymous testing to monitor chlamydia prevalence in young women in England? Pilot study incorporating randomised controlled trial of recruitment methods. Sex Transm Infect 2015; 91: 412–414.

43 Arnold DM, Burns KE, Adhikari NK, Kho ME, Meade MO, Cook DJ; McMaster Critical Care Interest Group. The design and interpretation of pilot trials in clinical research in critical care. Crit Care Med 2009; 37(Suppl): S69–S74.

44 Kraemer HC, Mintz J, Noda A, Tinklenberg J, Yesavage JA. Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch Gen Psychiatry 2006; 63: 484–489.

45 National Institute for Health Research. Applied Health Research in Surgery; 2012. https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/Surgery.pdf [accessed 14 January 2019].

46 Reinforcement of Closure of Stoma Site (ROCSS) Collaborative and the West Midlands Research Collaborative. Feasibility study from a randomized controlled trial of standard closure of a stoma site vs biological mesh reinforcement. Colorectal Dis 2016; 18: 889–896.

47 Morgan B, Hejdenberg J, Hinrichs-Krapels S, Armstrong D. Do feasibility studies contribute to, or avoid, waste in research? PLoS One 2018; 13: e0195951.

Supporting information
Additional supporting information can be found online in the Supporting Information section at the end of the article.